A randomized trial using in situ viral imaging and mass spectrometry reported that dolutegravir/lamivudine penetrated lymph node tissue and coincided with a rapid decline in HIV-1–infected cells. The imaging results were presented as evidence that the regimen can act where viral reservoirs persist, a key hurdle for durable suppression.